Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Seres Therapeutics (MCRB), BioMarin (BMRN) and Integra Lifesciences (IART).
Seres Therapeutics (MCRB)
H.C. Wainwright analyst Vernon Bernardino initiated coverage with a Buy rating on Seres Therapeutics today and set a price target of $16. The company’s shares closed yesterday at $5.83.
Bernardino said:
“We used a discounted cash flows (DCF) methodology to arrive at our 12-month price target of $16 for MCRB shares. Specifically, we discounted free cash flows for each year by 25%; divided them by our projected number of shares for each year to account for the effects of share dilution; and using a 2% terminal growth rate, and a probability-of-success of 72%, we derived an adjusted per share value of $16.06, which we rounded to $16. Seres ended 3Q18 with $73M in cash and equivalents, which we estimate operationally sufficient into 2H19.”
According to TipRanks.com, Bernardino is ranked #4855 out of 5194 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Seres Therapeutics with a $15.33 average price target, a 163.0% upside from current levels. In a report issued on February 7, Cantor Fitzgerald also maintained a Buy rating on the stock with a $15 price target.
See today’s analyst top recommended stocks >>
BioMarin (BMRN)
In a report released today, Leland Gershell from Oppenheimer maintained a Hold rating on BioMarin, with a price target of $81. The company’s shares closed yesterday at $88.81.
Gershell observed:
“BMRN reported 4Q revenue of $353M, within the mid-range of guidance, but below consensus of $377M, resulting from modest weakness across its core product offering vs. Street expectations. 2019 top-line guidance comes in-line with consensus, but below on net income. Palynziq continues to progress well in its US launch, facilitated by effort toward OLE conversions and some Kuvan switches. In 2H19 BMRN will decide on a potential accelerated approval submission for ValRox, and we expect important data increments on this investor-focused pipeline candidate in June/July as the collective clinical experience with hemophilia A gene therapies in development continues to evolve. We lower our PT to $81 from $92 consistent with our updated revenue expectations.”
According to TipRanks.com, Gershell is a 1-star analyst with an average return of -2.8% and a 30.6% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Evofem Biosciences Inc, AzurRx BioPharma Inc, and Urogen Pharma Ltd.
Currently, the analyst consensus on BioMarin is a Moderate Buy with an average price target of $122.60.
Integra Lifesciences (IART)
In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Integra Lifesciences, with a price target of $70. The company’s shares closed yesterday at $55.58.
Lichtman commented:
“IART’s Q4 sales were $383M; at the high-end of original $378-383M guidance and ahead of our $380M. Organic growth of 4.4% was above our 10 new product launches, the realigned/expanded OTT salesforce and international expansion. ’19 EPS guidance of $2.65-$2.72 (versus Street’s $2.65) implies 10-12% and includes solid EBITDA margin expansion (~100bps). FCF conversion also continues to increase.”
According to TipRanks.com, Lichtman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.2% and a 50.3% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Integra Lifesciences has an analyst consensus of Moderate Buy, with a price target consensus of $56.58, a 1.8% upside from current levels. In a report released yesterday, Piper Jaffray also reiterated a Buy rating on the stock with a $62 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
